MODERATORS
Paul%20Broom_edited.jpg

Paul Borm, PhD

  • Grey LinkedIn Icon

Moderator of Animal Studies

Paul Borm is expert in Toxicology and entrepreneur in Life Sciences and Medical Technology and. During his 25-year academic career in Toxicology (Utrecht, Maastricht, Düsseldorf) he conducted research into lung and cardiac diseases with a clear focus on occupational health exposure. In 2004
he co-founded a high-impact journal (PFT) for particle toxicology and he is the author of close to 200 publications. For 20 years now, Nanotechnologies feed his activities on regional and global level, and provide inspiration for both his research and business activities. In 2011 he founded Nano4Imaging GmbH which focuses on improvement of cardiovascular diagnosis and interventions using MRI, and Borm is responsible for clinical evaluation, post-marketing surveillance and MDR related issues. Borm acts as (strategic) consultant for several global companies and associations in the field chemicals, minerals and particles. In 2019 Borm has initiated, guided, organized, moderated and published a consensus opinion workshop on PSLT for all relevant stakeholders. Finally, he acts as a consultant in toxicology, expert assessments and due diligence on strategic and operational level. He still teaches Toxicology at post-graduate courses in NL and Germany, and medical imaging at Dusseldorf University.

Microphone Closeup

Robert Blink, PhD

  • Grey LinkedIn Icon

Moderator of Human Studies

Dr. Blink provides independent consulting services in Occupational and Environmental
Medicine, based in San Francisco, CA. He has served as Medical Director to employers, joint
labor-management health programs, a nationwide US medical provider network, a large group of hospitals in California, and is a member of the Scientific Advisory Group of ICBA. He is medical advisor to a federally-funded USA research project to reduce needless work disability. He holds leadership roles with the American College of Occupational and Environmental Medicine. He previously served on the California OSHA Standards Board. He currently serves as consultant to diverse industries including heavy industry, biotechnology, health care, and materials production.

Bob McCunney pic.jpg

Robert McCunney, MD, MPH, MS

  • Grey LinkedIn Icon

Moderator of Human Studies

Dr. McCunney is an internist who is also board certified in occupational and environmental medicine. He is a practicing physician in the Pulmonary Division of the Brigham and Women’s Hospital in Boston and a member of the Harvard Medical School faculty. His clinical and research practice focuses on occupational and environmental illnesses. Dr.  McCunney is former Director of Environmental Medicine at the Massachusetts Institute of Technology (MIT). As a visiting research professor at the Harvard School of Public Health, he regularly lectures and serves as a member of the residency advisory committee for occupational and environmental medicine residency program.

Dr. McCunney received a BS in chemical engineering from Drexel University, a MS in environmental health from the University of Minnesota, a MD from the Thomas Jefferson University Medical School and a MPH from the Harvard School of Public Health. He completed training in internal medicine at Northwestern University Medical Center in Chicago.

Dr. McCunney is past president of the American College of Occupational and Environmental Medicine (ACOEM), the world’s largest professional organization of physicians specializing in occupational and environmental medicine. He has edited five textbooks and over 115 peer-reviewed published articles and book chapters. Dr. McCunney is the Editor of all three editions of the textbook, A Practical Approach to Occupational and Environmental Medicine. He has received awards from international, national and regional medical societies over his career for his work in occupational and environmental medicine.

Nils%20Kruger_edited.jpg

Nils Krueger, PhD, DVM

  • Grey LinkedIn Icon

Moderator of Regulatory Application of Science

Dr Nils Krueger is a veterinarian and toxicologist with specialist training as a Board-Certified veterinary pathologist He has particular interests in particle and nanotoxicology for a wide number of substances and has a long experience of a range of EU and worldwide chemical regulatory requirements and issues. He is currently employed by Evonik as Head of the Hazard and Risk Assessment Group from the Smart Material Division and previously held positions there as Director of Toxicology.

Driscoll Photo.jpg

Kevin E. Driscoll, PhD

  • Grey LinkedIn Icon

Moderator of Nanoparticle toxicology -Pulmonary and Non-pulmonary challenges

Dr. Driscoll spent 30 years in Research & Development at the Procter & Gamble Company. As a basic research scientist, his laboratory studied molecular mechanisms of lung diseases and published over 150 technical papers. Subsequently, Dr. Driscoll created and led drug discovery and development organizations in P&G’s pharmaceutical and consumer health businesses. Most recently, he was a founding member of a joint venture between P&G and Teva Pharmaceuticals and led the JV’s global R&D, Regulatory and Medical organizations. Dr. Driscoll has a strong track record of bringing innovative healthcare products to market, including on key brands such as: Actonel, Prilosec, Vicks, ratiopharm, Metamucil and Swisse Vitamins.

Dr. Driscoll has served as an innovation and technology adviser to numerous companies, regulatory agencies and scientific organizations including: Board of Directors, Swiss Precision Diagnostics; Board of Trustees, BioStart; Board of Directors, BioOhio; US EPA and FDA; National Research Council; National Aeronautics & Space Administration (NASA); UK Health Safety Executive; and the World Health Organization. He is currently serving on the Board of Directors for ALLOKSYS, a clinical stage pharmaceutical company.

Dr. Driscoll received a B.S degree in Zoology from Western Illinois University and, Ph.D. and M.S. degrees in Environmental Health Science from New York University. He has held Adjunct faculty appointments in the University of Cincinnati, College of Medicine; the University of Rochester, School of Medicine and Dentistry; and is currently an Adjunct Professor at Rutgers University in the Ernest Mario School of Pharmacy.

Len%20Levy_edited.jpg

Len Levy, PhD

  • Grey LinkedIn Icon

Moderator of Regulatory Application of Science

Professor Levy is currently Emeritus Professor of Environmental Health at the University of Cranfield. Prior to this he was Head of Toxicology and Risk Assessment at the UK Medical Research Council's Institute for
Environment and Health at the University of Leicester. He is an occupational and environmental toxicologist and holds a doctorate in experimental pathology from the Institute of Cancer Research in London and has held academic positions at the University of Aston and the University of Birmingham's Institute of Occupational Health and has published more than 350 papers on occupational carcinogenesis, occupational and environmental toxicology, risk assessment and risk management and the regulatory aspects of environmental and occupational air standards. He has a particular interest in particle toxicology. He was also, until recently, Chair of the EU Scientific Committee on Occupational
Exposure Limits (SCOEL).

Jarabek_Annie_5x7_300dpi_edited.jpg

Annie Jarabek, PhD

  • Grey LinkedIn Icon

Moderator of Nanoparticle toxicology -Pulmonary and Non-pulmonary challenges

Annie M. Jarabek serves as a Senior Science Advisor in the immediate office of the Center for Public Health and Environmental Assessment (CPHEA) at its Health and Environmental Effects Assessment Division (HEEAD) in the Research Triangle Park, within the U.S. Environmental Protection Agency’s Office of Research and Development (ORD); following service as the Deputy Director of the Human Health Risk Assessment (HHRA) national research program in ORD.   Annie has significant experience and post-graduate training in inhalation toxicology in both laboratory and clinical environments, dosimetry modeling, risk assessment, and decision analysis.  She was principal author of the Agency’s Methods for Derivation of Inhalation Reference Concentrations and Application of Inhalation Dosimetry.  Annie has worked on risk assessments, dosimetry models or analysis methods across all media and routes of exposure.  She was the lead for the Agency’s risk assessment of ingested perchlorate and some of her other work addressed several priority interdisciplinary Agency assessments including:  inhaled particulate matter, vinyl acetate, manganese, and Libby amphibole asbestos.  Her current research efforts focus on multi-scale dosimetry modeling, including approaches for in vitro to in vivo extrapolation (IVIVE) of inhalation exposures to advance the application of emerging methods for translation and evidence integration across various experimental platforms.  She led the development of a user’s guide for the recently peer-reviewed EPA version of the multi-path particle dosimetry (MPPD) model which will serve as basis for a dosimetry workflow within Agency assessments.   A manuscript on her collaborative IVIVE work received an honorable mention as the best 2018 paper from the Biological Modeling Specialty Section (BMSS) at the 2019 annual Society of Toxicology (SOT) meeting, and another on integration of aggregate exposure pathways (AEP) and adverse outcome pathways (AOP) won best paper of the year from the Exposure Specialty Section of the SOT in 2020.  Annie has also received three awards for best manuscript in risk assessment application from the Risk Assessment Specialty Section (RASS) of the SOT, along with several best abstract presentation awards.  She received a Lifetime Achievement Award from the University of Massachusetts, the Risk Practitioner of the Year award from the Society of Risk Analysis (SRA), the Superfund National Notable Achievement Award, and several award medals (gold, silver and bronze) and technical or special service awards from the Agency.  Annie was most recently honored with the Lehman award for risk assessment by the SOT in 2020.